Warning: count(): Parameter must be an array or an object that implements Countable in /home/pulmonx6/public_html/wp-content/themes/specular/includes/view/blog/loop-grid.php on line 53

GOLD Treatment Recommendations for COPD Now Include Use of Endobronchial Valves to Treat Patients with Emphysema

Posted by Jenna Widdison
On November 18, 2016

Redwood City, Calif. – November 18, 2016 – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a substantial revision to its COPD management recommendations that now includes bronchoscopic lung volume reduction with endobronchial valves as a treatment option for patients with...

Posted by Jenna Widdison
On October 5, 2016

Redwood City, Calif. – October 5, 2016 – Pulmonx, a leader in interventional pulmonology, today announced completion of enrollment in its pivotal IDE study – the LIBERATE Trial – a randomized, controlled, multi-center study of the Zephyr® Endobronchial Valve (EBV) in patients with severe emphysema,...

Posted by Jenna Widdison
On September 5, 2016

Results Published in American Journal of Respiratory and Critical Care Medicine Show Meaningful Improvements in Patient Lung Function, Exercise Tolerance and Quality of Life

Posted by Jenna Widdison
On September 1, 2016

Cloud-Based Quantitative Computed Tomography (QCT) Analysis Service is Now Commercially Available

Posted by Jenna Widdison
On May 18, 2016

Redwood City, Calif. – May 18, 2016 - Pulmonx®, a leader in interventional pulmonology, today announced positive one year results from the groundbreaking STELVIO trial. The STELVIO trial is the first randomized controlled study of Zephyr® Endobronchial Valves (EBV) in severe emphysema patients...

Scroll

GOLD Treatment Recommendations for COPD Now Include Use of Endobronchial Valves to Treat Patients with Emphysema

Pulmonx Completes Enrollment in U.S. Pivotal Trial of Zephyr®Endobronchial Valve

New Study Demonstrates Benefits of Pulmonx Zephyr®Endobronchial Valve in Patients with Homogeneous Emphysema

New StratX Lung Analysis Platform from Pulmonx Enables Confident and Rapid Patient Selection for Zephyr® Endobronchial Valve Treatment

STELVIO Trial Shows Sustained Benefits for Emphysema Patients One Year After Treatment with Zephyr® Endobronchial Valves

Pulmonx Australia Suite 5, Level 6 65 York Street Sydney, NSW 2000 Australia

1300 785 666

info@pulmonx.com.au